| . | N = 73 . |
|---|---|
| Mild transient injection site reactions | 10 (13.6%) |
| Exanthema | 3 (4.1%) |
| Mild headache | 10 (13.6%) |
| Nausea | 1 (1.4%) |
| Malaise | 3 (4.1%) |
| Vertigo | 5 (6.8%) |
| . | N = 73 . |
|---|---|
| Mild transient injection site reactions | 10 (13.6%) |
| Exanthema | 3 (4.1%) |
| Mild headache | 10 (13.6%) |
| Nausea | 1 (1.4%) |
| Malaise | 3 (4.1%) |
| Vertigo | 5 (6.8%) |
Data are number (%).There were no severe and no unexpected adverse events related to the study drug anakinra, especially no neutropenia.
| . | N = 73 . |
|---|---|
| Mild transient injection site reactions | 10 (13.6%) |
| Exanthema | 3 (4.1%) |
| Mild headache | 10 (13.6%) |
| Nausea | 1 (1.4%) |
| Malaise | 3 (4.1%) |
| Vertigo | 5 (6.8%) |
| . | N = 73 . |
|---|---|
| Mild transient injection site reactions | 10 (13.6%) |
| Exanthema | 3 (4.1%) |
| Mild headache | 10 (13.6%) |
| Nausea | 1 (1.4%) |
| Malaise | 3 (4.1%) |
| Vertigo | 5 (6.8%) |
Data are number (%).There were no severe and no unexpected adverse events related to the study drug anakinra, especially no neutropenia.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
